Sage Therapeutics, Inc. financial data

Symbol
SAGE on Nasdaq
Location
55 Cambridge Parkway, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Jul 30, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 883 % -5.67%
Debt-to-equity 14.9 % +26.5%
Return On Equity -67.1 % -11%
Return On Assets -58.4 % -8.03%
Operating Margin -461 % +7.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.8M shares +2.84%
Common Stock, Shares, Outstanding 62.6M shares +2.85%
Entity Public Float 590M USD -76.1%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 62.6M shares +3.42%
Weighted Average Number of Shares Outstanding, Diluted 62.6M shares +3.42%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 70.4M USD -27.6%
Research and Development Expense 138M USD -54%
Operating Income (Loss) -325M USD +32.7%
Net Income (Loss) Attributable to Parent -301M USD +32.4%
Earnings Per Share, Basic -4 USD/shares +34%
Earnings Per Share, Diluted -4 USD/shares +34%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 67.5M USD -32.4%
Marketable Securities, Current 298M USD -45.5%
Accounts Receivable, after Allowance for Credit Loss, Current 16.3M USD +63.6%
Assets, Current 409M USD -40.4%
Property, Plant and Equipment, Net 674K USD -47.1%
Operating Lease, Right-of-Use Asset 9.96M USD +716%
Other Assets, Noncurrent 1.76M USD -77.5%
Assets 423M USD -39.3%
Accounts Payable, Current 692K USD -92%
Employee-related Liabilities, Current 10.7M USD -24.8%
Accrued Liabilities, Current 42.1M USD -28.7%
Liabilities, Current 44.6M USD -35.3%
Operating Lease, Liability, Noncurrent 9.54M USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 54.2M USD -21.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 15K USD
Retained Earnings (Accumulated Deficit) -3.08B USD -10.8%
Stockholders' Equity Attributable to Parent 369M USD -41.3%
Liabilities and Equity 423M USD -39.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -81.7M USD -116%
Net Cash Provided by (Used in) Financing Activities 148K USD -90.5%
Net Cash Provided by (Used in) Investing Activities 45.8M USD -67.2%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 62.6M shares +2.85%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -35.8M USD -135%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68.9M USD -32.9%
Deferred Tax Assets, Valuation Allowance 797M USD +8.37%
Deferred Tax Assets, Gross 797M USD +8.37%
Operating Lease, Liability 11.8M USD +129%
Depreciation 112K USD -66.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -300M USD +31.8%
Lessee, Operating Lease, Liability, to be Paid 15.4M USD
Property, Plant and Equipment, Gross 1.67M USD -82.2%
Operating Lease, Liability, Current 1.88M USD +33.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.98M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.46M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +40%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.58M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.06M USD
Deferred Tax Assets, Operating Loss Carryforwards 491M USD +14.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 8.28M USD +6.91%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.14M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 39.3M USD -45.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%